Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment

February 20, 2013 2:06 PM EST Send to a Friend
Get Alerts PSTI Hot Sheet
Trade PSTI Now!
Join SI Premium – FREE
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Insiders' Blog

Add Your Comment